Lobe Sciences Ltd., a clinical-stage biopharmaceutical company, welcomed the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders, viewing it as an important step enabling scientific research in areas historically difficult to study due to regulatory constraints. CEO Dr. Fred Sancilio stated, “We commend the White House for recognizing the need to advance research into serious neurological and mental health conditions. We believe that many investigational compounds should ultimately be removed from Schedule I classification and studied within standard pharmaceutical development frameworks.”
Lobe Sciences’ subsidiary, Cynaptec Pharmaceuticals, is developing L-130 as a non-hallucinogenic drug candidate as the industry continues to better understand this class of compounds. L-130 is currently being advanced for treatment of chronic cluster headache and substance use disorder. The company believes the evolving regulatory environment may stimulate broader research efforts and accelerate the development of new therapies for patients with serious neurological and mental health disorders. L-130 is a novel, patented, oral, and stable form of psilocin, the active metabolite of psilocybin, designed to enhance bioavailability and therapeutic efficacy, identified as having therapeutic potential in various neurological conditions. Conventional psilocin is an unstable compound challenging for the industry to develop as a standalone pharmaceutical, whereas L-130’s stability and bioavailability profile suggest potential for prescription drug development in various neurological and psychiatric indications. Lobe Sciences operates through a capital-efficient, subsidiary-based model, including a majority interest in Cynaptec Pharmaceuticals and its wholly owned subsidiary, Applied Lipid Technologies.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/accwirecq-2026-4-23-lobe-sciences-ltd-comments-on-white-house-executive-order-supporting-drug-development-for-neurological-and-mental-health-disorders